Merus secures EUR31m in series B round extension
Merus, a biopharmaceutical company focusing on human antibody therapeutics, has secured a EUR31m extension to its series B financing round, bringing the total round to EUR47.6m. Johnson & Johnson Development Corporation (JJDC) joined as a new investor along with existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City



